Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
复制标题
DOI：
10.3390/ijms17111800
复制
发表时间：
2016-10-27
影响因子：
5.6
通讯作者：
Nishiyama A
中科院分区：
文献类型：
--
作者：
Mizushige T;Kobori H;Hitomi H;Nishijima Y;Tomoda F;Morimoto S;Kohno M;Nishiyama A
本研究旨在证明尿血管紧张素原是奥美沙坦降低代谢综合征患者白蛋白尿作用的潜在预后标志物。24例患者（8例女性，57.88 ± 2.00岁）接受了5-40 mg/天奥美沙坦治疗。在奥美沙坦治疗12周和24周之前和之后测量尿白蛋白和血管紧张素原浓度（通过尿肌酐浓度标准化）以及血浆肾素活性。奥美沙坦治疗后血浆肾素活性显著升高，尿白蛋白和尿血管紧张素原显著降低（P < 0.05）。根据尿白蛋白的%变化，将患者分为两组，应答者（<-50%）和无应答者（≥-50%），治疗前尿血管紧张素原的logistic分析显示曲线下面积为0.694。当治疗前尿血管紧张素原的临界值为13.9 µg/g Cr时，获得最大的Youden指数（0.500，特异性：11/12 = 91.7%，敏感性：7/12 = 58.3%）。将所有患者重新分为治疗前尿血管紧张素原升高组（H组，n = 16）和治疗前尿血管紧张素原降低组（H组，n = 16），两组患者治疗后尿白蛋白明显降低（p < 0.05）。因此，尿血管紧张素原可作为奥美沙坦降低代谢综合征患者白蛋白尿疗效的一个预后指标。
This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome.
登录
查看更多内容
DOI：
10.1161/hypertensionaha.108.123802
发表时间：
2009-02
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Kobori H;Alper AB Jr;Shenava R;Katsurada A;Saito T;Ohashi N;Urushihara M;Miyata K;Satou R;Hamm LL;Navar LG
通讯作者：
Navar LG
影响因子：
8.3
作者：
Engeli, S;Bohnke, J;Sharma, AM
通讯作者：
Sharma, AM
DOI：
10.1016/j.jash.2008.04.008
发表时间：
2008-09-01
影响因子：
--
作者：
Kobori, Hiroyuki;Ohashi, Naro;Yamamoto, Tatsuo
通讯作者：
Yamamoto, Tatsuo
影响因子：
15.9
作者：
KAGAMI, S;BORDER, WA;NOBLE, NA
通讯作者：
NOBLE, NA
影响因子：
4.9
作者：
Fukuda, Michio;Urushihara, Maki;Kobori, Hiroyuki
通讯作者：
Kobori, Hiroyuki